PRTG Stock Overview
A clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Portage Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.62 |
| 52 Week High | US$40.80 |
| 52 Week Low | US$2.10 |
| Beta | 99.48 |
| 11 Month Change | -18.09% |
| 3 Month Change | -23.00% |
| 1 Year Change | -84.60% |
| 33 Year Change | -98.52% |
| 5 Year Change | 2,210.00% |
| Change since IPO | -99.31% |
Recent News & Updates
Shareholder Returns
| PRTG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 13.0% | 2.4% | 2.2% |
| 1Y | -84.6% | 16.2% | 31.7% |
Return vs Industry: PRTG underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: PRTG underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| PRTG volatility | |
|---|---|
| PRTG Average Weekly Movement | 51.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PRTG's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PRTG's weekly volatility has increased from 35% to 52% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 7 | Ian Walters | www.portagebiotech.com |
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials.
Portage Biotech Inc. Fundamentals Summary
| PRTG fundamental statistics | |
|---|---|
| Market cap | US$4.74m |
| Earnings (TTM) | -US$71.08m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs PRTG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRTG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$71.08m |
| Earnings | -US$71.08m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -67.77 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PRTG perform over the long term?
See historical performance and comparison